


# HD Research Data Access

## What data do you need?

Longitudinal data? Cross sectional data from multiple studies?

Ask us – we will help you!



Study	Summary	Duration	# participants	Participant segment	Clinical data	Family history	Imaging data	Brain morphometric/volumetric data	Other	File format	Data Access
<b>Enroll-HD</b>	Prospective, open-ended, multi-national, multi-center observational study without experimental treatments.	2012-	25,900	<ul style="list-style-type: none"> <li>Manifest HD</li> <li>Pre-manifest HD</li> <li>Genotype negative</li> <li>Genotype unknown</li> <li>Family Control</li> <li>Community Control</li> </ul>	Yes	Yes	No	No	GWAS (some), MiSeq (some), Methylation	CSV, R	<b>How to access:</b> <a href="http://www.enroll-hd.org">www.enroll-hd.org</a>
<b>REGISTRY</b>	Prospective, open-ended, European, multi-center observational study without experimental treatments.	2004 - 2017	13,000	<ul style="list-style-type: none"> <li>Manifest HD</li> <li>Pre-manifest HD</li> <li>Genotype negative</li> <li>Genotype unknown</li> <li>Family Control</li> <li>Community Control</li> </ul>	Yes	Partly	No	No	GWAS (some), MiSeq	CSV, R	<b>How to access:</b> Submit application to EHDN's Scientific Bioethic Advisory Board (SBAC), <a href="http://www.ehdn.org">www.ehdn.org</a>
<b>HDCSF/ HDClarity</b>	Study to collect high quality CSF samples for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. Enroll-HD platform study.	2017-present	600 Goal: 1200	<ul style="list-style-type: none"> <li>Early Pre-manifest HD</li> <li>Late Pre-manifest HD</li> <li>Early Manifest HD</li> <li>Mod. Manifest HD</li> <li>Late Manifest HD</li> <li>Control</li> </ul>	Yes	Yes	No	No	GWAS (some)	CSV	<b>How to access:</b> CHDI data use agreement
<b>TRACK-HD</b>	Multi-site international study aiming to establish what measurements were the best to use as 'outcome measures' for clinical trials in HD.	2008-2011	402	<ul style="list-style-type: none"> <li>Pre-manifest</li> <li>Early Manifest</li> <li>Control</li> </ul>	Yes	No	388 MRI; 237 DTI	Yes	GWAS, NFL	CSV, DCM	<b>How to access:</b> CHDI data use agreement
<b>TRACK-ON</b>	Extension of TRACK-HD	2012 – 2014	245	<ul style="list-style-type: none"> <li>Pre-manifest</li> <li>Early Manifest</li> <li>Control</li> </ul>	Yes	No	242 MRI; 241 fMRI; 239 DTI	Yes	GWAS, NFL	CSV, DCM	<b>How to access:</b> CHDI data use agreement
<b>COHORT</b>	Observational study designed to collect phenotypic data and samples from people with HD and their family members. North America and Australia.	2006 - 2011	2,318	<ul style="list-style-type: none"> <li>Manifest HD</li> <li>Pre-manifest HD</li> <li>Genotype unknown</li> <li>Family Control</li> </ul>	Yes	Yes	No	No		CSV	<b>How to access:</b> CHDI data use agreement
<b>PREDICT</b>	Purpose was to study early brain and behavioural changes in premanifest HD gene expansion carriers.	2006 - 2016	1,481	<ul style="list-style-type: none"> <li>Pre-manifest HD</li> </ul>	Yes	No	1,379 MRI; 103 fMRI	Yes		CSV, NII	<b>How to access:</b> CHDI data use agreement
<b>CARE-HD</b>	Co-Enzyme Q10 And Remacemide: Evaluation in HD	1997-2002	347	<ul style="list-style-type: none"> <li>Early HD</li> </ul>	Yes	No	No	No		SAS	<b>How to access:</b> CHDI data use agreement
<b>2CARE</b>	Coenzyme Q10 (CoQ) in Huntington Disease.	2003-2014	609	<ul style="list-style-type: none"> <li>Clinical features or confirmatory family history of HD OR CAG &gt;= 36</li> <li>Control</li> </ul>	Yes	No	No	No		SAS, XLSX	<b>How to access:</b> CHDI data use agreement
<b>HDYAS</b>	Huntington's Disease Young Adult Study	2017-2020	109	<ul style="list-style-type: none"> <li>Pre-manifest</li> <li>Gene Negative (Control)</li> <li>Family Control</li> <li>Community Control</li> </ul>	Yes	No	No	No	GFAP, hHb, IL6, IL8m mHTT, Neurogranin, NFL, TAU, totHTT, UCHL1, YKL40,	CSV	<b>How to access:</b> CHDI data use agreement
<b>CREST-E</b>	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	2009-2015	553	<ul style="list-style-type: none"> <li>Manifest HD, stage I or II of illness (TFC greater or equal to 7).</li> </ul>	Yes	No	No	No		SAS	<b>How to access:</b> CHDI data use agreement
<b>MTM-HD</b>	Multi Tissue Monitoring. Improved insight into disease-specific pathway/network alterations; Analysis of tissue samples from participating individuals will help to identify HD-related signatures	2015 - 2017	60	<ul style="list-style-type: none"> <li>Premanifest</li> <li>Early Manifest</li> <li>Control</li> </ul>	No	No	No	No	Miseq, WGS, Proteomics, Methylation, mRNaseq	CSV	<b>How to access:</b> CHDI data use agreement
<b>PACE-HD</b>	Physical Activity and Exercise outcomes in Huntington's Disease (PACE-HD)	2018-2020	116	<ul style="list-style-type: none"> <li>Manifest HD, up to and including Stage II disease (TFC 7-13)</li> </ul>	Yes	No	No	No		TBD	<b>How to access:</b> CHDI data use agreement
<b>Morphometric/Volumetric Neuroimaging</b>	Automated pipeline using the long FreeSurfer analysis method with manual review.	2017 – 2018	449 TRACK 1,313 PREDICT 111 IMAGE-HD		No	No	No	Yes		TSV	<b>How to access:</b> CHDI data use agreement